Strand Life Sciences, a subsidiary of Reliance Industries, has introduced CancerSpot, a blood-based test for early cancer detection. It employs methylation profiling technology to identify tumor DNA fragments from blood samples. The test is tailored using data from Indian cohorts, making it relevant globally. This initiative aligns with Reliance's goal of advancing healthcare through genomics.
